All In Biotech

Drug Trial Radar · NCT07270146

Effectiveness and Safety of Guilu Erxian Oral Liquid in the Treatment of Oligozoospermia and Asthenospermia With Syndrome of Shen (Kidney) Essence Deficiency

A Multicenter, Randomized, Double-blind, Positive Drug Controlled Clinical Trial on the Efficacy and Safety of Guilu Erxian Oral Liquid in the Treatment of Oligozoospermia and Asthenospermia With Syndrome of Shen (Kidney) Essence Deficiency

Last checked: Nov 20, 2026Latest source record: Dec 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 360 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

360

Actual

Start

Oct 8, 2022

Primary completion

Feb 10, 2025

Study completion Feb 10, 2025

Sponsor

Sponsor type
Industry
First posted
Dec 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 22 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main function of Guilu Erxian Oral Liquid is to warm the shen (kindney) and replenish essence. It is used for chronic shen (kindney) deficiency, waist and knee weakness, spermatorrhea and impotence. The treatment of deficiency of kidney essence and asthenospermia is to invigorate the shen (kindney) and replenish the essence, nourish the shen (kindney) and assist the essence. The idea of combining traditional Chinese and western medicine is to move the yang and calm the yin, and traditional Chinese medicine is mainly to invigorate the shen (kindney) and replenish the essence. In order to better provide the basis for clinical medication and meet the treatment needs of oligozoospermia and asthenospermia, this trial is intended to evaluate the effectiveness and safety of Guilu Erxian oral liquid in treating oligozoospermia and asthenospermia with Syndrome of Shen (Kidney) Essence Deficiency subjects.

Conditions

  • Mild and Moderate Oligozoospermia Asthenospermia or Oligoasthenospermia and the Syndrome Differentiation Type is Shen (Kidney) Essence Deficiency

Interventions

  • Guilu Erxian Oral LiquidDrug

    Guilu Erxian Oral Liquid+Wuzi Yanzong Oral Liquid Simulator

  • Wuzi Yanzong oral liquidDrug

    Wuzi Yanzong oral liquid+Guilu Erxian oral liquid simulator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total number of anterograde motile sperm (TPMSC)Time frame: 4,8,12 weeks after medical treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Xi Yuan Hospital of China Academy of Chinese Medical Sciences

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.